Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: A prospective cohort study

Journal of Internal Medicine

Volumn 270, Issue 1, 2011, Pages 32-40

  Huttunen, R ^a,b   Syrjanen J ^a,b   Vuento, R ^c   Hurme, M ^b,c   Huhtala, H ^d   Laine, J ^a   Pessi, T ^d   Aittoniemi, J ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^c PIRKANMAA HOSPITAL DISTRICT   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Bacteraemia; Biomarker; Outcome; Sepsis; Soluble urokinase type plasminogen activator receptor; SuPAR

Indexed keywords

CREATININE; UROKINASE RECEPTOR;

ADULT; AGED; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BETA HEMOLYTIC STREPTOCOCCUS; BLOOD CULTURE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; ESCHERICHIA COLI; FATALITY; FEMALE; HEART DISEASE; HUMAN; HYPOTENSION; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATION; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROVASCULAR ENDOTHELIAL CELL; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SENSIBILITY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 79959331335     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02363.x     Document Type: Article

References (24)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
2. Marshall JC, Reinhart K. Biomarkers of sepsis. Crit Care Med 2009; 37: 2290-8.
3. Huttunen R, Syrjänen J, Aittoniemi J et al. High activity of indoleamine 2, 3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 2010; 33: 149-54.
4. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12: 613-20.
5. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 157-72.
6. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000; 165: 1513-9.
7. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507-11.
8. Wiersinga WJ, Kager LM, Hovius JW et al. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol 2010; 184: 3079-86.
9. Tarui T, Mazar AP, Cines DB, Takada Y. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001; 276: 3983-90.
10. Wittenhagen P, Kronborg G, Weis N et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004; 10: 409-15.
11. Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-5.
12. Lawn SD, Myer L, Bangani N, Vogt M, Wood R. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis 2007; 7: 41.
13. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004; 36: 14-9.
14. Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002; 6: 686-92.
15. Kofoed K, Andersen O, Kronborg G et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007; 11: R38.
16. Eugen-Olsen J, Andersen O, Linneberg A et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296-308.
17. Huttunen R, Laine J, Lumio J, Vuento R, Syrjänen J. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia. BMC Infect Dis 2007; 7: 13.
18. Huttunen R, Aittoniemi J, Laine J et al. Gene-environment interaction between MBL2 genotype and smoking, and the risk of gram-positive bacteraemia. Scand J Immunol 2008; 68: 438-44.
19. Huttunen R, Hurme M, Laine J et al. Endothelial nitric oxide synthase G894T (Glu298Asp) polymorphism is associated with hypotension in patients with E. coli bacteremia but not in bacteremia caused by a gram-positive organism. Shock 2009; 31: 448-53.
20. McCabe WR. Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Arch Intern Med 1962; 110: 856-64.
21. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
22. Boyd JC. Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest Suppl 1997; 227: 46-63.
23. Brunner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999; 107: 160-7.
24. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77.